Alexander Sinclair-Wilson
Principal @ Qiming Venture Partners
London, United Kingdom
Alexander Sinclair-Wilson is a Series A investor at Qiming Venture Partners in London focused on Biotechnology and Medical. Dr. Alexander Sinclair-Wilson holds the esteemed position of Principal at Qiming Venture Partners, where he plays a pivotal role in driving investment strategies and fostering innovation within the venture capital landscape.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Alexander Sinclair-Wilson invests in
Stages Alexander Sinclair-Wilson invests in
Countries Alexander Sinclair-Wilson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Life Science 1 (25%)
Stage
- Series A 2 (50%)
- Series B 1 (25%)
- Funding Round 1 (25%)
Country
- Switzerland 1 (25%)
- United Kingdom 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | |
Immutrin
|
Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M / Series A / Mar 24, 2026 | |
|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M / Series A / Jan 10, 2025 | |
|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. |
Co-Investors
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Qiming Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Grace Lee
Partner & CFO
|
|||
Jinda Gao
Principal
|
|||
Oscar Zhang
Principal
|
|||
Shiyu Wang
Partner
|
|||
|
Alexander Sinclair-Wilson
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexander Sinclair-Wilson invest in?
Alexander Sinclair-Wilson invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexander Sinclair-Wilson?
Public channels for Alexander Sinclair-Wilson include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexander Sinclair-Wilson last invest?
The most recent investment recorded for Alexander Sinclair-Wilson closed in May 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
